1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Atenolol |
| brand | String | Tenormin |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Beta blockers|Beta blocker (cardioselective β1)]] • [[:Category:Antihypertensives|Antihypertensive]] |
| mechanism | String | |
| uses | String | '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"' |
| starting_dose | String | 25-50 mg PO once daily; titrate to 100 mg/day |
| preparations | String | Tablets 25, 50, 100 mg |
| fda_max | String | 100-200 mg/day depending on indication |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral |
| onset | String | BP effect within hours; full effect over 1-2 weeks |
| duration | String | 24 hours (once-daily dosing supported by long elimination) |
| halflife | String | 6-9 hours (substantially longer in renal impairment due to renal elimination)'"`UNIQ--ref-00000020-QINU`"' |
| bioavailability | String | ~50% (oral)'"`UNIQ--ref-00000021-QINU`"' |
| pregnancy | String | '''Documented fetal growth restriction with chronic exposure'''; avoid in pregnancy if alternative β-blockers are appropriate. The β-blocker most consistently associated with intrauterine growth concerns'"`UNIQ--ref-00000022-QINU`"' |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US |
